First Australian Guideline for Pediatric Hypertension Identification and Management

This inaugural Australian pediatric hypertension guideline, adapted from the AAP 2017 framework, gives pharmacists a unified national reference for BP thresholds, screening timing, and antihypertensive selection in patients under 18 years of age.

📅 Journal publication: Jul 14, 2026 · Last updated: Aug 31, 2026

Australian Guideline for Hypertension in Children and AdolescentsBPOzKids NetworkHypertension Australiapaediatric hypertensionchronic kidney diseaseACE inhibitorsARBscalcium channel blockersthiazide diuretics Pediatric Pharmacy

Background Information

New guidelines tackle rising pediatric hypertension issues.

Hypertension in children and adolescents is a growing concern, requiring specific guidelines for effective management. The guideline provides updated criteria for diagnosis and recommendations for management strategies. These guidelines help standardize the approach to diagnosing and managing pediatric hypertension, an area with previously limited resources. New guidelines aim to improve hypertension management in young populations through standardized practices.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Larkins NG, Medley T, Black A, Bolton KA, Chaturvedi S, Clark M, Gabb GM, Glenning JP, Grimes C, Huang RC, Hyland A, Jeffries-Stokes C, Kalman L, Kaul S, Kim S, McTaggart S, Kowalski R, Li SX, McNab S, Metz D, Mihailidou AS, Monin J, Nelson M, Pathak M, Roebuck D, Schlaich MP, Sleaby R, Quinlan C, Mynard JP

Citation: Larkins NG, Medley T, Black A, et al. Australian Guideline for the Identification and Management of Hypertension in Children and Adolescents. Journal of paediatrics and child health. 2026. doi:10.1111/jpc.70491

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →